Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

The federal health insurance program has selected 15 additional drugs covered by Medicare Part D for its next round of price ...

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

Medicare announced Friday that it has selected 15 drugs, including the hugely popular medications Ozempic and Wegovy, used for diabetes and weight loss, as well as some blockbuster cancer ...

Collectively, the top eight blockbuster drugs of 2024 generated over $116 billion in sales last year. Looking closer at these ...

Insurers also ask the Trump administration, which is engaged in a sweeping campaign to eradicate anything related to ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations ...

In one of its last actions, the Biden administration released the next 15 drugs selected for Medicare negotiation and the blockbuster diabetes drug Ozempic will be among those bargained for this year.

Among the 10 drugs listed, Medicare Part D spent the most on Ozempic, Rybelsus and Wegovy, at $14.43 billion, according to a CMS fact sheet on Friday. Nearly 2.3 million enrollees used those drugs ...

If Robert F. Kennedy Jr. and the Trump administration want to make America healthy again, they should let Medicare cover ...

WASHINGTON (AP) — Popular weight loss and diabetes drugs like Ozempic and Wegovy have been added to Medicare’s list of medications that will be negotiated directly between the government and ...

According to CMS data, Medicare Part D spending on Ozempic was more than $4.6 billion in 2022. Ozempic has become emblematic of the explosive enthusiasm for GLP-1 medications in the U.S. Danish ...